Skip to main content

Medication Overuse Headache in Patients with Primary Headache Disorders

Epidemiology, Management and Pathogenesis

CNS Drugs volume 19, pages 483–497 (2005)Cite this article

Abstract

Medication overuse headache (MOH) is a common medical condition that is associated with considerable long-term morbidity and disability. Patients experiencing MOH have primary headache disorders (migraine, tension-type headache [TTH] or the combination of migraine and TTH) that change to a pattern of daily or near-daily headaches over a period of years or decades following the overuse of symptomatic headache medications. Overused drugs include analgesics, ergot alkaloids, serotonin 5-HT1b/1d receptor agonists (‘triptans’) and medications containing barbiturates, codeine, caffeine, tranquillisers and mixed analgesics. Affected patients usually have a long history of primary headache, overuse of medications and MOH before they consult a physician for care. Patients with MOH are usually managed in specialist centres by withdrawal of the overused drugs and treatment of withdrawal symptoms (on an inpatient or outpatient basis), headache prophylaxis and limited use of symptomatic acute medications. Most patients respond to this therapy, although the prognosis is not always good and ≥50% may lapse over an initial 5-year follow-up period. The best practical strategy at present is to prevent the overuse of drugs in the first place by patient education and formal management approaches conducted in primary care to treat the primary headache before it changes to MOH. The quality of the clinical evidence on MOH is suboptimal and further biological and clinical research is urgently required to help facilitate the management of these patients more effectively in the future.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

49,54 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

Fig. 1
Table I
Table II
Table III
Table IV
Table V
Table VI

References

  1. Silberstein SD, Lipton RB. Chronic daily headache. Curr Opin Neurol 2000; 13: 277–83

    PubMed  Article  CAS  Google Scholar 

  2. Dowson AJ. Your questions answered: migraine and other headaches. Edinburgh: Churchill Livingstone, 2003

    Google Scholar 

  3. Headache Classification Subcommittee of the International Headache Society. The international classification of headache disorders. Cephalalgia 2004; 24 Suppl. 1: 1–160

    Google Scholar 

  4. Peters GA, Horton BT. Headache: with special reference to excessive use of ergotamine preparations and withdrawal effects. Mayo Clin Proc 1951; 26: 214–26

    Google Scholar 

  5. Mathew NT. Chronic refractory headache. Neurology 1993; 43(6 Suppl. 3): 26–33

    Google Scholar 

  6. Sanin LC, Mathew NT, Bellmeyer LR, et al. The International Headache Society (IHS) headache classification as applied to a headache clinic population. Cephalalgia 1994; 14: 443–6

    PubMed  Article  CAS  Google Scholar 

  7. Dowson AJ. Analysis of the patients attending a specialist UK headache clinic over a 3-year period. Headache 2003; 43: 14–8

    PubMed  Article  Google Scholar 

  8. Mathew NT. Transformed migraine. Cephalalgia 1993; 13 Suppl. 12: 78–83

    Google Scholar 

  9. Stewart WF, Lipton RB, Celentano DD, et al. Prevalence of migraine headache in the United States; relation to age, income, race, and other sociodemographic factors. JAMA 1992; 267: 64–9

    PubMed  Article  CAS  Google Scholar 

  10. Hagen K, Vatten L, Stovner LJ, et al. Low socio-economic status is associated with increased risk of frequent headache: a prospective study of 22 718 adults in Norway. Cephalalgia 2002; 22: 672–9

    PubMed  Article  CAS  Google Scholar 

  11. Silberstein SD, Young WB. Analgesic rebound headache: how great is the problem and what can be done? Drug Saf 1995; 13: 133–44

    PubMed  Article  CAS  Google Scholar 

  12. Castillo J, Munoz P, Guitera V, et al. Epidemiology of chronic daily headache in the general population. Headache 1999; 39: 190–6

    PubMed  Article  CAS  Google Scholar 

  13. Rapoport A, Stang P, Gutterman DL, et al. Analgesic rebound headache in clinical practice: data from a physician survey. Headache 1996; 36: 14–9

    PubMed  Article  CAS  Google Scholar 

  14. Eggen AE. The Tromsø study: frequency and predicting factors of analgesic drug use in a free living population (12–56 years). J Clin Epidemiol 1993; 46: 1297–304

    PubMed  Article  CAS  Google Scholar 

  15. Gutzwiller F, Zemp E. Der analgetikakonsum in der Bevölkerung und socioökonomische aspekte des analge-tikaabusus. In: Mihatsch MJ, editor. Das Analgetikasyndrom. Stuttgart: Thieme, 1986: 197–205

    Google Scholar 

  16. Schwarz A, Farber U, Glaeske G, et al. Dated zu analgetikakonsum und analgetikanephropathie in der bundesrepublik. Offen-tiches Gesundheitswesen 1985; 47: 298–300

    CAS  Google Scholar 

  17. Celentano DD, Stewart WF, Lipton RB, et al. Medication use and disability among migraineurs: a national probability sample. Headache 1992; 32: 223–8

    PubMed  Article  CAS  Google Scholar 

  18. Robinson RG. Pain relief for headaches. Can Fam Physician 1993; 39: 867–72

    PubMed  CAS  Google Scholar 

  19. Von Korff M, Galer BS, Stang P. Chronic use of symptomatic headache medications. Pain 1995; 62: 179–86

    Article  Google Scholar 

  20. Schnider P, Aull S, Feucht M, et al. Use and abuse of analgesics in tension-type headache. Cephalalgia 1994; 14: 162–7

    PubMed  Article  CAS  Google Scholar 

  21. Micieli G, Manzoni GC, Granella F, et al. Clinical and epidemiological observations on drug abuse in headache patients. In: Diener H-C, Wilkinson M, editors. Drug-induced headache. Berlin: Springer-Verlag, 1988: 20–8

    Chapter  Google Scholar 

  22. Rapoport AM. Analgesic rebound headache. Headache 1988; 28: 662–5

    PubMed  Article  CAS  Google Scholar 

  23. Solomon S, Lipton RB, Newman LC. Clinical features of chronic daily headache. Headache 1992; 32: 325–9

    PubMed  Article  CAS  Google Scholar 

  24. Silberstein SD, Saper J. Migraine: diagnosis and treatment. In: Dalessio D, Silberstein SD, editors. Wolff ’s headache and other head pain. New York: Oxford University Press, 1993: 96–170

    Google Scholar 

  25. Diener H-C, Tfelt-Hansen P. Headache associated with chronic use of substances. In: Olesen J, Tfelt-Hansen P, Welch KMA, editors. The headaches. New York: Raven Press, 1993: 721–7

    Google Scholar 

  26. Zwart J-A, Dyb G, Hagen K, et al. Analgesic use: a predictor of chronic pain and medication overuse headache. The Head-HUNT Study. Neurology 2003; 61: 160–4

    Google Scholar 

  27. Lipton RB, Bigal ME. Chronic daily headache: is analgesic overuse a cause or a consequence? Neurology 2003; 61: 154–5

    PubMed  Article  Google Scholar 

  28. Limmroth V, Kazarawa S, Fritsche G, et al. Features of medication overuse headache following overuse of different acute headache drugs. Neurology 2002; 59: 1011–4

    PubMed  Article  CAS  Google Scholar 

  29. Meyler WJ. Side effects of ergotamine. Cephalalgia 1996; 16: 5–10

    PubMed  Article  CAS  Google Scholar 

  30. Silberstein SD, Lipton R, Solomon S, et al. Classification of daily and near daily headaches: proposed revisions to the IHS classification. Headache 1994; 34: 1–7

    Article  Google Scholar 

  31. Baumgartner C, Wessely P, Bingöl C, et al. Long term prognosis of analgesic withdrawal in patients with drug-induced headaches. Headache 1989; 29: 10–4

    Article  Google Scholar 

  32. Diener H-C, Bühler K, Dichgans J, et al. Analgetikainduzierter Dauerkopfschmerz. Existiert eine kritische Dosis? Arzneimitteltherapie 1988; 6: 156–64

    Google Scholar 

  33. Mathew NT, Kurman R, Perez F. Drug induced refractory headache: clinical features and management. Headache 1990; 30: 634–8

    PubMed  Article  CAS  Google Scholar 

  34. Silverman K, Evans SM, Strain EC, et al. Withdrawal syndrome after the double-blind cessation of caffeine consumption. N Engl J Med 1992; 327: 1109–14

    PubMed  Article  CAS  Google Scholar 

  35. Feinstein AR, Heinemann LA, Dalessio D, et al. Do caffeine-containing analgesics promote dependence? A review and evaluation. Clin Pharmacol Ther 2000; 68: 457–67

    PubMed  Article  CAS  Google Scholar 

  36. Williams D, Cahill T, Dowson A, et al. Usage of triptans among migraine patients: an audit in nine GP practices. Curr Med Res Opin 2002; 18: 1–9

    PubMed  CAS  Google Scholar 

  37. Gaist D, Andersen M, Aarup AL, et al. Use of sumatriptan in Denmark in 1994–5: an epidemiological analysis of nationwide prescription data. Br J Clin Pharmacol 1997; 43: 429–33

    PubMed  Article  CAS  Google Scholar 

  38. Gaist D, Hallas J, Sindrup SH, et al. Is overuse of sumatriptan a problem? A population-based study. Eur J Clin Pharmacol 1996; 50: 161–5

    PubMed  Article  CAS  Google Scholar 

  39. Gaist D, Tsiropoulus I, Sindrup SH, et al. Inappropriate use of sumatriptan: population based register and interview study. BMJ 1998; 316: 1352–3

    PubMed  Article  CAS  Google Scholar 

  40. Pini LA, Trenti T. Case report: does chronic use of sumatriptan induce dependence? Headache 1994; 34: 600–1

    PubMed  Article  CAS  Google Scholar 

  41. Katsarava Z, Fritsche G, Muessig M, et al. Clinical features of withdrawal headache following overuse of triptans and other headache drugs. Neurology 2001; 57: 1694–8

    PubMed  Article  CAS  Google Scholar 

  42. Katsarava Z, Diener H-C, Limmroth V. Medication overuse headache: a focus on analgesics, ergot alkaloids and triptans. Drug Saf 2001; 24: 921–7

    PubMed  Article  CAS  Google Scholar 

  43. Limmroth V, Kazarawa S, Fritsche G, et al. Headache after frequent use of new 5-HT agonists zolmitriptan and naratriptan [letter]. Lancet 1999; 353: 378

    PubMed  Article  CAS  Google Scholar 

  44. Evers S, Gralow I, Bauer B, et al. Sumatriptan and ergotamine overuse and drug-induced headache: a clinicoepidemiologic study. Clin Neuropharmacol 1999; 22: 201–6

    PubMed  CAS  Google Scholar 

  45. Diener H-C, Katsarava Z. Medication overuse headache. Curr Med Res Opin 2001; 17 Suppl. 1: 17–21

    Article  Google Scholar 

  46. Silberstein SD, for the US Headache Consortium. Practice parameter: evidence-based guidelines for migraine headache (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2000; 55: 754–762

    PubMed  Article  CAS  Google Scholar 

  47. Dowson AJ, Lipscombe S, Sender J, et al. New guidelines for the management of migraine in primary care. Curr Med Res Opin 2002; 18: 414–39

    PubMed  Article  CAS  Google Scholar 

  48. Zed PJ, Loewen PS, Robinson G. Medication-induced headache: overview and systematic review of therapeutic approaches. Ann Pharmacother 1999; 33: 61–72

    PubMed  Article  CAS  Google Scholar 

  49. Diener H-C, Dahlöf CGH. Headache associated with chronic use of substances. In: Olesen J, Tfelt-Hansen P, Welch KMA, editors. The headaches. 2nd ed. Philadelphia (PA): Lippincott Williams and Wilkins, 1999: 871–8

    Google Scholar 

  50. Haag G, Baar H, Grotemeyer KH, et al. Prophylaxe und Therapie des medikamenteninduzierten Dauerkopfschmerzes. Schmerz 1999; 13: 52–7

    PubMed  Article  CAS  Google Scholar 

  51. Hering-Hanit R, Cohen A, Horev Z. Successful withdrawal from analgesic abuse in a group of youngsters with chronic daily headache. J Child Neurol 2001; 16: 448–9

    PubMed  CAS  Google Scholar 

  52. Symon DN. Twelve cases of analgesic headache. Arch Dis Child 1998; 78: 555–6

    PubMed  Article  CAS  Google Scholar 

  53. Panconesi A, Del Bianco PL, Curradi C, et al. Headache caused by analgesic and/or ergotamine abuse [in Italian]. Clin Ter 1991; 137: 169–83

    PubMed  CAS  Google Scholar 

  54. Krymchantowski AV, Barbosa JS. Prednisone as initial treatment of analgesic-induced daily headache. Cephalalgia 2000; 20: 107–13

    PubMed  Article  CAS  Google Scholar 

  55. Diener H-C, Haab J, Peters C, et al. Subcutaneous sumatriptan in the treatment of headache during withdrawal from drug-induced headache. Headache 1990; 31: 205–9

    Article  Google Scholar 

  56. Mathew NT. Amelioration of ergotamine withdrawal with naproxen. Headache 1987; 27: 130–3

    PubMed  Article  CAS  Google Scholar 

  57. Williams DR, Stark RJ. Intravenous lignocaine (lidocaine) infusion for the treatment of chronic daily headache with substantial medication overuse. Cephalalgia 2003; 23: 963–71

    PubMed  Article  CAS  Google Scholar 

  58. Diener H-C, Dichgans J, Scholz E, et al. Analgesic-induced chronic headache: long-term results of withdrawal therapy. J Neurol 1989; 236: 9–14

    PubMed  Article  CAS  Google Scholar 

  59. Descombes S, Brefel-Courbon C, Thalamas C, et al. Amitriptyline treatment in chronic drug-induced headache: a double-blind comparative pilot study. Headache 2001; 41: 178–82

    PubMed  Article  CAS  Google Scholar 

  60. Jevoux CC, Moreira Filho PF, de Souza JA. Primary chronic daily headache: a report on 52 cases [in Portuguese]. Arq Neuropsiquiatr 1998; 56: 69–77

    Google Scholar 

  61. Bonuccelli U, Nuti A, Lucetti C, et al. Amitriptyline and dexamethasone combined treatment in drug-induced headache. Cephalalgia 1996; 16: 198–200

    PubMed  Article  CAS  Google Scholar 

  62. Mathew NT, Ali S. Valproate in the treatment of persistent chronic daily headache: an open labelled study. Headache 1991; 31: 71–4

    PubMed  Article  CAS  Google Scholar 

  63. Smith TR. Low-dose tizanidine with nonsteroidal anti-inflammatory drugs for detoxification from analgesic rebound headache. Headache 2002; 42: 175–7

    PubMed  Article  Google Scholar 

  64. Tribl GG, Schnider P, Wöber C, et al. Are there predictive factors for long-term outcome after withdrawal in drug-induced chronic daily headache? Cephalalgia 2001; 21: 691–6

    PubMed  Article  CAS  Google Scholar 

  65. Fritsche G, Eberl A, Katsarava Z, et al. Drug-induced headache: long-term follow-up of withdrawal therapy and persistence of drug misuse. Eur Neurol 2001; 45: 229–35

    PubMed  Article  CAS  Google Scholar 

  66. Pini L-A, Cicero AFG, Sandrini M. Long-term follow-up of patients treated for chronic headache with analgesic overuse. Cephalalgia 2001; 21: 878–83

    PubMed  Article  CAS  Google Scholar 

  67. Katsarava Z, Limmroth V, Finke M, et al. Rate and predictors for relapse in medication overuse headache: a one year prospective study. Neurology 2003; 60: 182–3

    Article  Google Scholar 

  68. Katsarava Z, Muessig M, Dzagnidze A, et al. Medication overuse headache: rates and predictors for relapse in a 4-year prospective study, Cephalagia 2005; 25: 12–15

    CAS  Google Scholar 

  69. Barone-Kaganas I. Drug-induced headache and its treatment. Schweiz Med Wochenschr 1999; 129: 446–9

    PubMed  CAS  Google Scholar 

  70. Burstein R, Yarnitsky D, Good-Aryeh I, et al. An association between migraine and cutaneous allodynia. Ann Neurol 2000; 47: 614–24

    PubMed  Article  CAS  Google Scholar 

  71. Burstein R, Cutrer M, Yarnitzky D. The development of cutaneous allodynia during migraine attacks: clinical evidence for the sequential recruitment of spinal and supraspinal nociceptive neurons in migraine. Brain 2000; 123: 1703–9

    PubMed  Article  Google Scholar 

  72. Welch KMA, Nagesh V, Aurora SK, et al. Periaqueductal gray matter dysfunction in migraine: cause or the burden of illness? Headache 2001; 41: 629–37

    PubMed  Article  CAS  Google Scholar 

  73. Srikiatkhachorn A. Chronic daily headache: a scientist’s perspective. Headache 2002; 42: 532–7

    PubMed  Article  Google Scholar 

  74. Ekbom K, Krabbe A, Micieli G, et al. Cluster headache attacks treated for up to three months with subcutaneous sumatriptan (6 mg). Cephalalgia 1995; 15: 230–6

    PubMed  Article  CAS  Google Scholar 

  75. Bahra A, Walsh M, Menon S, et al. Does chronic daily headache arise de novo in association with regular analgesic use? Headache 2003; 43: 179–90

    PubMed  Article  Google Scholar 

  76. Weiller C, May A, Limmroth V, et al. Brain stem activation in spontaneous migraine attacks. Nat Med 1995; 1: 658–60

    PubMed  Article  CAS  Google Scholar 

  77. Saucier C, Morris SJ, Albert PR. Endogenous serotonin-2A and-2C receptors in Balb/c-3T3 cells revealed in serotonin-free medium: desensitization and down-regulation by serotonin. Biochem Pharmacol 1998; 56: 1347–57

    PubMed  Article  CAS  Google Scholar 

  78. Cox BM. Drug tolerance and physical dependence. In: Pratt WB, Taylor P, editors. Principles of drug action: the basis of pharmacology. Churchill Livingstone: New York, 1990: 639–90

    Google Scholar 

  79. Foley KM. Opioids. Neurol Clin 1993; 11: 503–22

    PubMed  CAS  Google Scholar 

  80. Foley KM. Misconceptions and controversies regarding the use of opioids in cancer pain. Anticancer Drugs 1995; 6 Suppl. 3: 4–13

    Article  Google Scholar 

  81. Arner S, Rawal N, Gustafsson LL. Clinical experience of long-term treatment with epidural and intrathecal opioids: a nationwide survey. Acta Anaesthesiol Scand 1988; 32: 253–9

    PubMed  Article  CAS  Google Scholar 

  82. Devulder J. Hyperalgesia induced by high-dose intrathecal sufentanil in neuropathic pain. J Neurosurg Anesthesiol 1997; 9: 146–8

    PubMed  Article  CAS  Google Scholar 

  83. Eisenach JC. Preemptive hyperalgesia, not analgesia? Anesthe-siology 2000; 92: 308–9

    Article  CAS  Google Scholar 

  84. Yaksh TL, Kohl RL, Rudy TA. Induction of tolerance and withdrawal in rats receiving morphine in the spinal subarach-noid space. Eur J Pharmacol 1977; 42: 275–84

    PubMed  Article  CAS  Google Scholar 

  85. Yaksh TL, Harty GJ, Onofrio BM. High doses of spinal morphine produce a nonopiate receptor-mediated hyperesthesia: clinical and theoretic implications. Anesthesiology 1986; 64: 590–7

    PubMed  Article  CAS  Google Scholar 

  86. Yaksh TL, Harty GJ. Pharmacology of the allodynia in rats evoked by high dose intrathecal morphine. J Pharmacol Exp Ther 1988; 244: 501–7

    PubMed  CAS  Google Scholar 

  87. Mao J, Price DD, Mayer DJ. Mechanisms of hyperalgesia and morphine tolerance: a current view of their possible interactions. Pain 1995; 62: 259–74

    PubMed  Article  CAS  Google Scholar 

  88. Vanderah TW, Gardell LR, Burgess SE, et al. Dynorphin promotes abnormal pain and spinal opioid antinociceptive tolerance. J Neurosci 2000; 20: 7074–9

    PubMed  CAS  Google Scholar 

  89. Vanderah TW, Suenaga NMH, Ossipov MH, et al. Tonic descending facilitation from the rostral ventromedial medulla mediates opioid-induced abnormal pain and antinociceptive tolerance. J Neurosci 2001; 21: 279–86

    PubMed  CAS  Google Scholar 

  90. Claude P, Gracia N, Wagner L, et al. Effect of dynorphin on ICGRP release from capsaicin-sensitive fibers.Abstracts of the Ninth World Congress on Pain; Vienna 1999

  91. Pryse-Phillips WEM, Dodick DW, Edmeads JG, et al. Guidelines for the diagnosis and management of migraine in clinical practice. CMAJ 1997; 156: 1273-87

    PubMed  CAS  Google Scholar 

Download references

Acknowledgements

The writing of this article was funded, in part, by an unrestricted educational grant from Merck, Sharp & Dohme. The authors have no conflicts of interest relating to the content of the manuscript.

Author information

Affiliations

  1. The King’s Headache Service, King’s College Hospital, Denmark Hill, London, SE5 9RS, UK

    Andrew J. Dowson

  2. Mayo Clinic, Scottsdale, Arizona, USA

    David W. Dodick

  3. Department of Neurology, University Hospital Essen, Essen, Germany

    Volker Limmroth

Authors
  1. Andrew J. Dowson
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. David W. Dodick
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Volker Limmroth
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Andrew J. Dowson.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Dowson, A.J., Dodick, D.W. & Limmroth, V. Medication Overuse Headache in Patients with Primary Headache Disorders. CNS Drugs 19, 483–497 (2005). https://doi.org/10.2165/00023210-200519060-00002

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00023210-200519060-00002

Keywords

  • Migraine
  • Sumatriptan
  • Chronic Migraine
  • Zolmitriptan
  • Ergotamine